Abstract
Importance Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive malignancy which is associated with subtle local invasion and metastasis. Near-infrared (NIR) fluorescence-guided surgical precise resection of the tumor margin and potential metastasis has been appealing.
Objective To determine whether a peptide-based NIR fluorescence dye, which can be administered via topical application and target tumor tissue via c-MET binding, can improve discrimination of HNSCC from normal tissue.
Design A nonrandomized controlled trial was conducted between March 2021 and February 2022 at Shanghai Ninth Peoples’ Hospital, China. Study participants were blinded for subjective measurements.
Setting Exploratory, single-center, open-label, dose-escalation
Participants Consecutive Asian individuals with clinically suspicious, primary or recurrent HNSCC, who were scheduled for standard-of-care surgery with curative intent, were enrolled.
Interventions Enrolled patients underwent in vivo fluorescence imaging before surgery, and ex vivo fluorescence imaging was performed on intraoperative specimens using 2.5 μM or 5.0 μM topical applicated fluorescent probes.
Main Outcomes and Measures Primary analysis compared mean fluorescence intensity (MFI, total fluorescence signal divided by the total number of pixels within the region of interest) of tumor and peritumoral normal tissue. Possible tumor-to-background ratios (TBR, ratio of MFI of tumor over peritumoral normal tissues) may range from 2 to 4.
Results Ten patients (1 female [10%], age = 59.4 ± 12.6 years old) were enrolled. Ex vivo imaging with 5.0 μM fluorescence prob demonstrated TBR of 2.71 ± 0.7, with 2.5 μM fluorescence prob demonstrated TBR of 3.11 ±1.2. To discriminate tumor from normal tissue with MFI, the area under the curve (AUC) was 0.88 (95% CI-0.88 to 1.0) for the 5.0 μM group, and 0.65 (95% CI 0.53 to 0.83) for the 2.5 μM group.
Conclusions and Relevance This trial demonstrates that topical application of tumor targeting fluorescence probe can differentiate tumor and outlining tumor margins. Further research is currently underway to estimate whether this probe is potent in guiding biopsy and surgical procedure, and assisting long-term follow-up postoperatively.
Trial Registration Chinese Clinical Trial Registry Identifier: ChiCTR2200058058
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2200058058
Funding Statement
This work was funded by the National Scientific Foundation of China (91859202 and 82172049).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review board of Chinese Clinical Trial Registry (ChiCTR2200058058) and medical ethics committee of the Shanghai Ninth People's Hospital Affiliatedaffiliated to the Shanghai Jiaotong University, schoolSchool of medicineMedicine (SH9H-2020-T147-2)gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: tian{at}ieee.org
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
